• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Centrifugal-flow devices noninferior to axial-flow in advanced heart failure: The ENDURANCE trial

byJames RoebkerandShaidah Deghan, MSc. MD
February 3, 2017
in Cardiology, Chronic Disease, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Centrifugal-flow left ventricular assist devices (LVAD) were found to be noninferior to traditional axis-flow devices for the treatment of New York Heart Association (NYHA) class IIIb and IV heart failure refractory to medial therapy.

2. Though there was a significantly lower rate of device failure requiring surgical intervention, centrifugal-flow devices demonstrated a significantly higher rate of stroke, right heart failure, and sepsis.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: The shortage of effective medical therapy for patients with advanced heart failure has lead to technological advances in mechanical circulatory devices. LVADs have demonstrated increased survival and improved quality of life among heart failure patients. However, the risks of infection, neurologic events, and pump failure must be balanced with the clinical benefits of LVADs. The ENDURANCE trial assessed the safety and efficacy of the centrifugal-flow LVAD (study device) compared to the traditional axial-flow device (control). At the two year mark, the LVAD demonstrated to be noninferior comparing to the traditional axial-flow device in regards to disabling stroke and device malfunction. Among secondary endpoints, the centrifugal-flow device was associated with a significantly higher incidence of stroke, right heart failure, and sepsis; however, patients in the axial-flow control group were more likely to have device malfunction requiring surgical pump exchange or transplantation. Limitations of the included the use of individualized anticoagulation and antiplatelet regimens that may have impacted adverse events, a change in study device design during the trial, and the failure to assess durability beyond 2 years.

Click to read the study, published in NEJM

Relevant Reading: A fully magnetically levitated circulatory pump for advanced heart failure

In-Depth [randomized controlled trial]: In this trial, 466 patients were randomized to the study device (intention-to-treat group, n = 297) or control (n = 148) in a 2:1 ratio. Eligibility criteria included patients with NYHA class IIIb or IV heart failure, left ventricular ejection fraction below 25%, and who were ineligible for transplant at the time of enrollment. The primary outcome was a composite of 2-year survival free from disabling stroke and device malfunction that required surgery or urgent implantation. Secondary endpoints included prespecified major adverse events, overall survival, and changes in quality of life defined by clinically validated questionnaires. Two thirds of participants received a modified (sintered) device during the course of the trial, and a separate analysis of the primary endpoint was done in this subgroup.

RELATED REPORTS

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

Clinical decision-making strategy improves acute heart failure outcomes

Ferric derisomaltose may reduce heart failure-related hospitalizations

The study device was found to be noninferior to the control device in the analysis of the primary endpoint (estimated success rates based on a Weibull model, 55.4% and 59.1%, respectively; upper one-sided CI, 12.56 percentage points; p = 0.01 for noninferiority). The sintered device was also found to be noninferior in the subgroup analysis. The Kaplan-Meier estimated survival without stroke or device replacement at 2 years was 55.0% with the study device and 57.4% with the control device (p = 0.67). Conpared to the study group, a higher percentage of patients in the control group reported device malfunction or failure requiring exchange, explantation, or urgent transplantation (8.8% vs. 16.2%, respectively). Furthermore, a within the first six months a significantly higher incidence of both ischemic and hemorrhagic stroke were reported in the study group compared to placebo (29.7% vs. 12.1%, p < 0.001). The study device also had significantly higher rates of right heart failure (38.5% vs. 26.8%, p = 0.02) and sepsis (23.6% vs. 15.4%, p = 0.048). No significant difference was found in all other secondary outcomes, including functional status and quality of life.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: heart failureLVAD
Previous Post

Adding antiandrogen therapy to radiation improves overall survival in recurrent prostate cancer

Next Post

Laser therapy may be effective in patients with infantile hemangiomas

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

January 24, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
No association found between length of storage for transfused red blood cells and patient mortality
Cardiology

Ferric derisomaltose may reduce heart failure-related hospitalizations

December 27, 2022
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Next Post
Laser therapy may be effective in patients with infantile hemangiomas

Laser therapy may be effective in patients with infantile hemangiomas

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

2 Minute Medicine Rewind February 6, 2017

Significant percentage of pediatricians dismiss families who refuse vaccines

Recommendations for Childhood and Adolescent Immunizations

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options